Citations

Clear

9383 citation(s) found for "Thomas, PS".

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
Cerhan, James R. , Соколова, Т. Н. , Cahn, Elliot, Tsang, Mazie , Strouse, Christopher , Hildebrandt, Michelle A.T. , Feldman, Andrew L. , Jaye, David L. , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Thompson, Carrie A. , Flowers, Christopher R. , Sokolova, Tereza, Cahn, Elliott J, Strouse, Christopher S , Rosenthal, Allison , Feldman, Andrew L , Jaye, David L , Martin, Peter , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Friedberg, Jonathan W , Nastoupil, Loretta J , Link, Brian K , Habermann, Thomas , Maurer, Matthew , Casulo, Carla , Thompson, Carrie A , Williams, Annalynn M , Flowers, Christopher R , Cerhan, James R , Hildebrandt, Michelle A T , Tsang, Mazie , Sokolova, Tereza, Kahl, Brad S. , Nastoupil, Loretta J. , Link, Brian K. , Habermann, Thomas M. , Maurer, Matthew J. , Casulo, Carla

Mayo Clinic

Hematological Oncology | October 8, 2025 | Volume: 43 | Issue: 6 | Pages: No page available

10.1002/hon.70137 | PMID 41057230 Get It

ABSTRACT Newly diagnosed patients with non‐Hodgkin lymphoma (NHL) often have a history of other diseases, and these comorbidities can impact patient treatment and management options, as well as overall survival (OS). We developed the Lymphoma Epidemiology of Outcomes (LEO) comorbidity index (LCI) as a sum of 10 comorbidities adapted from the Self‐Report‐Generated Charlson Comorbidity Index (SRG‐CCI) for use in the LEO cohort, a national prospective study of newly diagnosed NHL. Of the 5502 participants with self‐reported comorbidity data, 3107 (56.4%) were male and the mean age at diagnosis was 60.9 years (range, 18–99 years). The LCI ranged from 0 to 6, with 48.6% having 0, 30.2% having 1, 21.2% having 2 or more comorbidities. With a median follow‐up of 62.4 months among surviving participants, 2099 patients had an event and 1219 died. Continuous LCI similarly predicted both 1‐year mortality (c‐statistic = 0.654) and OS (c‐statistic = 0.655), while it showed a weaker but still statistically significant predictive ability for lymphoma‐specific (c‐statistics = 0.617) and event‐free (c‐statistic = 0.574) survival. Participants with 1 (HR = 1.21, 95% CI 1.05–1.39) and 2+ (HR = 1.80, 95% CI 1.56–2.08) comorbidities had inferior OS compared to those with no comorbidities after adjustment for age and sex (c‐statistic = 0.654), and performance strengthened after adjustment for the International Prognostic Index (c‐statistic = 0.672). LCI predicted OS most strongly in marginal zone (c‐statistics = 0.748) and weakest in T‐cell (c‐statistic = 0.579) lymphoma. The cumulative incidence of death due to lymphoma, lymphoma treatment, and other causes all increased with increasing comorbidities, with the greatest increase observed for death due to other causes. The LCI performs comparable to other published comorbidity indices, supporting its use in the LEO cohort to better model real‐world outcomes and more generally providing an approach to implementing comorbidity indices in cancer survivorship cohorts.
Deep Learning‐Based MRI Volumetry for Living Kidney Donor Assessment: A New Tool for Predicting Post‐Donation Renal Function
Koch, Dominik , Hofmann, Felix O. , Trompoukis, Dimitrios , Schirren, Malte , Jacobi, Severin , Seibt, Tobias , Kemmner, Stephan , Scheifele, Maximilian, Werner, Jens , Stangl, Manfred , Guba, Markus , Koliogiannis, Dionysios , Koch, Dominik Thomas , Ilmer, Matthias, Ilmer, Matthias , Renz, Bernhard Willibald

Mayo Clinic

Clinical Transplantation | October 8, 2025 | Volume: 39 | Issue: 10 | Pages: No page available

10.1111/ctr.70338 | PMID 41055603 Get It

ABSTRACT Background Living kidney donation is a crucial option for addressing the global organ shortage and providing kidney transplantation for patients suffering from end‐stage kidney disease. Ensuring donor safety necessitates a comprehensive preoperative assessment of kidney anatomy and function. This study evaluates the relationship between kidney volumes derived from deep learning‐based MRI volumetry, intraoperative kidney volume measurements, split renal function measured by renal scintigraphy, and post‐donation eGFR. Deep learning‐based MRI volumetry is hypothesized to be a reliable method with good correlation. Methods This retrospective study analyzed 178 living kidney donors. Deep learning MRI volumetry‐based kidney volumes were compared with intraoperative volumes of the explanted donor kidneys obtained using the water displacement method. Additionally, MRI‐based volume ratios were compared with scintigraphy‐based split renal function ratios to determine their ability to predict the kidney with poorer renal function and post‐donation eGFR. Results Deep learning‐based MRI volumetry strongly correlated with intraoperatively measured kidney volumes (Pearson's correlation; r = 0.7671; p < 0.0001), confirming its precision in volume estimation. Although MRI‐based kidney volume ratios demonstrated only a moderate correlation with scintigraphy‐based split renal function ratios ( r = 0.4798), MRI volumetry correlated with 1‐year post‐donation eGFR. It tended to be better than renal scintigraphy ( r = 0.6829 versus r = 0.6191). Conclusion Deep learning‐based MRI volumetry is a reliable, non‐invasive tool for estimating kidney volumes in living donors, offering a radiation‐free alternative for preoperative assessment. While it differs from renal scintigraphy in evaluating split renal function ratios, its correlation with post‐donation eGFR tends to be better, supporting its potential role in living kidney donor assessment.
Machine learning analysis of continuous body temperature data to differentiate between infectious and non-infectious fevers in bone marrow transplant recipients.
Khan, Shihan N. , Madhukar, Rashmi, Leopold, Kay E., Choi, Sung Won , Tewari, Muneesh , Choi, Sung Won , Lee, Seungwoo , Rozwadowski, Michelle , Weinberg, Jason B. , Paludo, Jonas , Binder, Adam Finn , Sung, Anthony D.

Mayo Clinic

JCO Oncology Practice | October 7, 2025 | Volume: 21 | Issue: 10_suppl | Pages: 592-592

10.1200/op.2025.21.10_suppl.592 Get It

592 Background: While not all fevers occurring during hematopoietic stem cell transplantation (HCT) are dangerous, episodes of febrile neutropenia tend to be managed aggressively given the significant mortality and morbidity associated with infectious complications of transplantation. This can potentially lead to unnecessary diagnostic testing, antibiotic treatment, and prolonged hospital stays for non-infectious fever etiologies such as engraftment. Our group has previously demonstrated that high-frequency body temperature monitoring (HFTM) using a wearable device detects fevers earlier in transplant recipients (Flora et al, Cancer Cell, 2021). We hypothesized that applying supervised machine learning to HFTM data collected from inpatient allogeneic HCT patients would allow for accurately distinguishing between non-infectious and infectious etiologies of fever and could potentially guide safe de-escalation of antibiotics. Methods: We analyzed 74 independent fever events detected in HCT patients (n=42) outfitted with an FDA-cleared, wireless sensor measuring axillary temperatures every 2 minutes for the duration of their respective hospitalizations. After data filtering, independent fever events were then retrospectively grouped by fever etiology using physician-determined annotation as previously described (Flora et al., 2021). A split ratio of 80:20 was used to create training and test sets from the parent data set, consisting of 59 and 15 fever events for each split, respectively. Training sets were used to create a classification algorithm identifying bacterial infections requiring antibiotics using the machine learning model XGBoost. The performance of this model was then evaluated using test sets of the remaining fevers (n=15). Results: Averaging over 1000 test sets of 15 independent fevers comprising 5 bacterial infection-related fevers and 10 non-infectious fevers, our model correctly identified 82% (mean recall) of cases requiring antibiotics with a mean precision of 0.41. The model also correctly identified 42% of non-infectious fevers (mean true negative rate, 0.42) that would otherwise have been treated with unnecessary antibiotics. The mean AUCPR was 0.58, with the best performing individual model achieving an AUCPR of 0.97. Conclusions: The preliminary results of this study demonstrate that our classification model shows promise for differentiating fevers requiring antibiotics due to bacterial infections from other non-infectious fever etiologies. Prospective studies further developing supervised machine learning models for subcategorization of febrile neutropenia could pave the way for safely de-escalating antibiotics in HCT and other immunocompromised patients undergoing cancer treatment monitored using HFTM.
Common peroneal nerve schwannomas around the knee: a surgical case series of 44 patients and systematic review of the literature
Ruiter, Godard C. W. de , Hayford, Kirsten M., Vissers, Thomas , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | October 4, 2025 | Volume: 144 | Issue: 1 | Pages: 217-227

10.3171/2025.5.jns25705 | PMID 41043186 Get It

OBJECTIVE Resection of common peroneal nerve (CPN) schwannomas is generally believed to be associated with a high risk of postoperative deficit, especially the chance for development of a foot drop. The goal of this study was to investigate the surgical results for resection of schwannomas from the CPN around the knee and specifically the chance of developing a postoperative motor deficit. METHODS Data from 36 patients with sporadic schwannomas and 8 patients with schwannomatosis (12 schwannomas total) treated at two centers were retrospectively analyzed. For sporadic cases, different locations around the knee were compared (i.e., proximal to the fibular head [FH], at the FH, and distal to the FH), taking into account the preoperative duration of symptoms, size at presentation, and surgical results of resection. The literature was systematically reviewed for reported cases by searching the PubMed and Embase databases. RESULTS A total of 24 schwannomas proximal to the FH were surgically treated: 11 at the FH, and 13 distal to the FH. For the entire cohort, the mean size of CPN schwannomas distal to the FH at presentation was smaller (1.4 × 1.8 cm) compared with those proximal to (2.0 × 2.2 cm) and at (2.2 × 2.3 cm) the FH, although these differences were not statistically significant. The mean preoperative duration of symptoms was slightly longer for schwannomas distal to the FH (35 months) than for those proximal to the FH (21 months) and at the FH (27 months); however, this difference was not significant. Postoperative deficits occurred in 3 sporadic cases: 2 patients with temporary weakness (Medical Research Council grade 4) that completely resolved within several months and 1 patient who had previously undergone surgery elsewhere and presented with deficits and in whom weakness increased after resection. Improvement in preoperative deficits was observed in 1 patient with extensor hallucis longus muscle paralysis that completely recovered. One patient with schwannomatosis developed muscle weakness after resection of a plexiform schwannoma. A systematic review of 21 previously reported cases in the literature showed that larger CPN schwannomas (> 5 cm) were more likely to result in permanent motor deficits. CONCLUSIONS This retrospective study of 44 patients shows that peroneal nerve schwannomas around the knee can be safely removed with a low risk of deficits. The systematic review of the literature suggests that larger schwannomas are more likely to result in permanent deficit. In the authors’ opinion, CPN schwannomas can best be resected, preferably when the lesion is relatively small.
Achieving and Sustaining Standardized Measurement of Treatment Outcomes in Children With Cleft Lip/Palate: Pilot Study of a Multifaced Implementation Strategy
Sitzman, Thomas J. , Chee-Williams, Jessica L. , Cordero, Kelly Nett , Beals, Patricia, Britto, Maria T. , Sitzman, Thomas J , Chee-Williams, Jessica L , Singh, Davinder

Mayo Clinic

The Cleft Palate Craniofacial Journal | October 3, 2025 | Volume: 63 | Issue: 8 | Pages: 2493-2502

10.1177/10556656251382528 | PMID 41042928 Get It

Objective Prior work has identified numerous barriers to standardized outcome measurement in cleft care. The objective of this study was to evaluate a multifaceted implementation strategy to collect standardized outcomes for children with cleft lip and/or palate (CL/P). Design A one-armed, single-site pilot study of a multifaceted implementation strategy. Setting A metropolitan children's hospital. Patients Five-year-old children with CL/P. Interventions A multifaceted implementation strategy for standardized outcome measurement. Main Outcomes Measures The primary outcome measure was penetration of the intervention, defined as the proportion of children for whom the standardized measures of aesthetic, dental, and speech outcomes were collected. Penetration pre-implementation and 12 months post-implementation were compared. The secondary outcome was acceptability of standardized outcome measurement among providers and staff, evaluated with the Acceptability of Intervention Measure. Results The implementation strategy resulted in high penetration of standardized outcome measurement: measurement of aesthetic outcomes increased from 7% to 82% ( p < .0001); measurement of dental outcomes increased from 0% to 56% ( p < .0001); measurement of speech outcomes increased from 29% to 77% ( p = .0001). Acceptability of standardized outcome measurement was high, with 93% of cleft team providers and staff (n = 14/15) reporting that they somewhat or completely agreed that standardized outcome measurement met their approval, was appealing, was welcomed, and was liked. Penetration continued to improve after the implementation period, with high rates of outcome measure collection sustained for four years following implementation. Conclusions Deployment of a multifaceted implementation strategy led to substantial increases in the collection of aesthetic, dental, and speech outcomes among children with CL/P.
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
Garsed, Dale W. , Pandey, Ahwan , Ariyaratne, Dinuka , Laumont, Céline M. , Hamilton, Phineas T. , Alsop, Jennifer , Antoniou, Antonis C. , Au‐Yeung, George , Beckmann, Matthias W. , González, Amy Berrington de , Bisinotto, Christiani, Blome, Freya , Bodelón, Clara , Boros, Jessica , Brand, Alison H. , Carney, Michael E., Coulson, Penny , Cushing‐Haugen, Kara L. , Cybulski, Cezary, Darcy, Kathleen M. , David, C. W. Mabey, Davidson, Trent , Emons, Julius , Farrell, Rhonda , Gentry-Maharaj, Aleksandra, Harter, Philipp, Hartmann, Arndt, Heikaus, Sebastian, Hettiaratchi, Anusha , Heublein, Sabine , Huntsman, David G. , Jimenez-Linan, Mercedes , Jones, Michael E. , Kang, Eunyoung , Konecny, Gottfried E. , Kruitwagen, Rutgerus, Kwon, Jessica, Lambrechts, Diether , Lester, Jenny, Leung, Samuel , Leung, Yee , Loverix, Liselore , Mateoiu, Constantina , McNeish, Iain A. , Nevins, Nikilyn, Olawaiye, Alexander , Oršulić, Sandra , Osório, Ana , Quinn, Carmel M. , Mohan, Ganendra Raj , Ruebner, Matthias , Salfinger, Stuart , Samra, Spinder , Stewart, Colin J.R. , Talhouk, Aline , Tan, Adeline , Tarney, Christopher M., Aa, Maaike AVan Der, Gorp, Toon Van , Nieuwenhuysen, Els Van, Wagensveld, Lilian van , Wahner-Hendrickson, Andrea E., Walter, Christina B., Welz, Julia , Wentzensen, Nicolas , Winterhoff, Boris , Berchuck, Andrew, Fasching, Peter A. , Gayther, Simon A. , Kelemen, Linda E. , Maxwell, G. Larry , Menon, Usha , Modugno, Francesmary, Schildkraut, Joellen M. , Staebler, Annette , Swedlow, Anthony, Vergote, Ignace , Wu, Anna H. , Pearce, Celeste Leigh, Pike, M. C., Goode, Ellen L. , Bowtell, David D.L. , Lambrechts, Diether , Garsed, Dale W , Fereday, Sian , Pandey, Ahwan , Ariyaratne, Dinuka , Kennedy, Catherine J , Milne, Katy , Berrington de Gonzalez, Amy , Blome, Freya , Bodelon, Clara , Christie, Elizabeth L , Ekici, Arif B , Ghatage, Prafull , Hettiaratchi, Anusha , Jones, Michael E , Kommoss, Felix , Lambrechts, Diether , Lee, Cheng-Han , Leung, Yee , Linder, Anna , McNeish, Iain A , Nelson, Gregg S , Nevins, Nikilyn , Ray-Coquard, Isabelle L. , Roxburgh, Patricia , Van de Vijver, Koen , Wahner-Hendrickson, Andrea, Wang, Chen , Wentzensen, Nicolas , Winham, Stacey J , Anglesio, Michael S , Cohen, Paul , Conrads, Thomas , Fasching, Peter A , Horlings, Hugo , Karlan, Beth Y , Menon, Usha , Neuhausen, Susan L. , Brenton, James D , Pharoah, Paul D P , Goode, Ellen L , Ramus, Susan J , Köbel, Martin , Nelson, Brad H , Fazio, Anna de , Friedlander, Michael , Lambrechts, Diether , Brand, Alison H , Bowtell, David D , Goodman, Marc T , Zwimpfer, Tibor A. , Fereday, Sián , Jayawardana, Madawa , Twomey, Laura , Kennedy, Catherine J. , Bolithon, Adelyn , Meagher, Nicola S. , Milne, Katy , Cazorla, Alicia , Chiu, Derek S , Christie, Elizabeth L. , Chudecka-Glaz, Anita Monika , Ekici, Arif B. , Elishaev, Esther , Engler, Tobias , Fischer, Anna, García‐Closas, Montserrat , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Hartkopf, Andreas D , Hernandez, Brenda Y. , Kaznowska, Ewa B. , Kluz, Tomasz , Kruitwagen, Roy F.P.M. , Kwon, Jessica, Lee, Cheng‐Han , Lester, Jenny, Leung, Samuel, Linder, Anna , Lissowska, Jolanta , Lubiński, Jan , Moubarak, Malak , Nelson, Gregg , Olbrecht, Siel , Rodríguez‐Antona, Cristina , Schoemaker, Minouk J. , Sinn, Hans‐Peter , Sonke, Gabe S. , Steele, Linda, Taylor, Sarah E , Nieuwenhuysen, Els Van , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Anglesio, Michael S. , Reis, Francisco José Cândido dos , Cohen, Paul A. , Crowe, Philip John , Doherty, Jennifer A. , Fortner, Renée T. , García, María J. , Goodman, Marc T. , Gronwald, Jacek , Harris, Holly R. , Heitz, Florian , Karlan, Beth Y. , Sundfeldt, Karin , Brenton, James D. , Pharoah, Paul D.P. , Ramus, Susan J. , Köbel, Martin , Nelson, Brad H. , DeFazio, Anna , Friedländer, Michael

Mayo Clinic

No container title available | October 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7572112/v1 | PMID 41255967 Get It

Abstract BRCA-associated homologous recombination deficiency (HRD) is present in ~ 50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA-deficient tumors experience unexpectedly poor outcomes. We profiled 154 tumors, enriched for patients with BRCA-deficient tumors that experienced short overall survival (≤ 3 years, n = 42), using whole-genome, transcriptome, and methylation analyses. All but one BRCA-deficient tumor exceeded an accepted HRD genomic scarring threshold. However, patients with BRCA1-deficient HGSC with a more elevated HRD score survived significantly longer. Patients with BRCA2-deficient HGSC and loss of NF1 survived twice as long as those without NF1 loss, whereas PIK3CA or RAD21 amplification defined BRCA2-deficient HGSC with exceptionally short survival. BRCA1-deficient tumors in short survivors had evidence of immunosuppressive c-kit signaling and EMT. In a large HGSC cohort (n = 1,389) including 282 individuals with pathogenic germline BRCA variants (gBRCApv), the location of the mutation within functional domains stratified clinical outcomes. Notably, residual disease after primary surgery had limited prognostic effect in gBRCApv-carriers compared to non-carriers. Our findings indicate that tumor HR proficiency in the context of therapy response and survival is not a binary property, and highlight genomic and immune modifiers of outcomes in BRCA-deficient HGSC.
OS09.5.A RECURRENT COPY NUMBER ALTERATIONS DRIVE IDH-MUTANT ASTROCYTOMA DEVELOPMENT AND PROGRESSION
Zadeh, Gelareh, Jenkins, Robert B. , Haider, Shozeb , Drucker, Kristen , Tsai, R, Al‐Zahrani, Khalid N. , Chiu, C H, Kollmeyer, Thomas M. , Schramek, Daniel

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii24-iii24

10.1093/neuonc/noaf193.071 Get It

Abstract BACKGROUND IDH-mutant gliomas are diffusely infiltrating, slow-growing brain tumors that inevitably undergo malignant progression to grade IV astrocytoma - a highly aggressive and uniformly fatal disease with dismal prognosis. Despite extensive research, the molecular mechanisms underlying this transformation remain poorly understood. While alterations in canonical driver genes such as CDKN2A, PTEN, and PDGFRA have been implicated, the broader landscape of genetic drivers involved in IDH-mutant glioma progression is largely uncharacterized. In contrast to many other malignancies, IDH-mutant gliomas acquire relatively few somatic point mutations during progression - typically in the range of 30 to 40 - suggesting that alternative mechanisms may be driving tumor evolution. Notably, these tumors exhibit widespread chromosomal instability, resulting in a heterogeneous and highly prevalent pattern of copy number alterations (CNAs). This observation raises the possibility that gene dosage changes due to CNAs play a critical role in tumor progression. MATERIAL AND METHODS To investigate this hypothesis, we performed integrative analysis of IDH-mutant glioma cohorts from the Mayo Clinic and TCGA datasets (~1,500 patients), identifying twelve highly recurrent CNAs significantly associated with patient outcomes. We refer to these as malignant IDH-associated CNAs (mIDH CNAs). We hypothesized that these recurrent CNAs harbor driver genes that confer selective growth advantages, thereby contributing to their recurrence and prognostic relevance. To systematically assess the functional impact of genes within these regions, we developed a novel in vivo CRISPR-based screening platform, termed CRISPR-Knock Out and Activation Linked Assay (CRISPR-KOALA). This approach utilizes stereotaxic delivery of lentiviral gRNA libraries - targeting mouse orthologs of ~1,800 genes within recurrently deleted regions and ~1,200 genes within amplified regions - into the brains of a genetically engineered mouse model of IDH-mutant glioma (rs557mut;IDHmut;P53KO;AtrxKO;Cas9GFP: Yanchus et. al Science 2022). RESULTS Mice injected with mIDH CNA-targeting libraries developed tumors significantly more rapidly than control cohorts. Deconvolution of the CRISPR-KOALA screen identified several putative driver genes, including regulators of the NOTCH signaling pathway, lipid metabolism modulators such as THEM6, and the NMDA receptor modulator GRINA - implicating dysregulation of metabolism, immune response, and glutamatergic signaling in the malignant transformation of IDH-mutant gliomas. CONCLUSION Together, these findings provide critical insights into the genetic mechanisms driving the progression of IDH-mutant gliomas and identify new candidate genes and pathways for potential therapeutic targeting.
Cardiopulmonary exercise testing before lung resection surgery: still indicated? Evaluating predictive utility using machine learning
Filakovszky, Ákos , Tschoellitsch, Thomas , Bartos, Stepan, Mazur, Andrej, Meier, Jens , Olson, Lyle J. , Olson, Lyle, Cundrle, Ivan , Brat, Kristián , Mazur, Andrej, Čundrle, Ivan

Mayo Clinic

Thorax | October 3, 2025 | Volume: 81 | Issue: 5 | Pages: 474-482

10.1136/thorax-2024-221485 | PMID 41043965 Get It

Rationale Despite significant advances in patient care and outcomes, criteria for cardiopulmonary exercise testing (CPET) in risk stratification guidelines for lung resection have not been updated in over a decade. We hypothesised that CPET no longer holds additional predictive value for postoperative complications. Methods In this secondary analysis, we included lung resection candidates from two prospective, multicentre studies eligible for CPET and assessed with preoperative pulmonary function tests (PFTs) and arterial blood gas analysis. Postoperative pulmonary (PPCs) and cardiovascular complications (PCCs) were documented during hospitalisation. We trained five types of machine learning models applying nested cross-validation to predict complications and compared predictive performance based on four metrics, including area under the receiver operating characteristic curve (AUC-ROC). Results A total of 497 patients were included. PPCs developed in 71 (14%) patients. Adding CPET parameters to PFTs and baseline clinical data did not improve the ability of models to predict PPCs in unselected patients (AUC-ROC=0.72–0.78; p=0.47), nor in those meeting American College of Chest Physicians (ACCPs) (n=236; AUC-ROC=0.64–0.78; p=0.70) or European Respiratory Society/European Society of Thoracic Surgery (ERS/ESTS) criteria (n=168; AUC-ROC=0.59–0.76; p=0.92). PCCs developed in 90 (18%) patients. CPET parameters likewise did not improve model performance for the prediction of PCCs in unselected patients (AUC-ROC=0.65–0.73; p=0.96), nor in the ACCP (AUC-ROC=0.61–0.73; p=0.82) or ERS/ESTS subgroups (AUC-ROC=0.62–0.69; p=0.87). Conclusions In contemporary surgical practice, CPET did not improve the predictive performance of machine learning models for PPCs or PCCs in patients with an indication based on established guidelines or in those without. The role of CPET in preoperative risk stratification for lung resection should be re-evaluated. Trial registration number NCT03498352 , NCT04826575 .
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations
Ostrowski, Micah , Lin, Edwin , Srivastava, Ayana , Gordhamer, Abigail, Ji, Richard, Li, Haoran , Gupta, Sumati , Maughan, Benjamin L. , Agarwal, Neeraj , Swami, Umang , Riaz, Irbaz Bin , Jo, Yeonjung , Chehade, Chadi Hage , Özay, Zeynep İrem , Gebrael, Georges , Sayegh, Nicolas , Thomas, Vinay Mathew , Roy, Soumyajit, Agarwal, Neeraj

Mayo Clinic

JAMA Network Open | October 2, 2025 | Volume: 8 | Issue: 10 | Pages: e2534968

10.1001/jamanetworkopen.2025.34968 | PMID 41037269 Get It

ImportancePatients with metastatic castration–resistant prostate cancer (mCRPC) harboring BRCA1/2 alterations are eligible to receive poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as single agents or in combination with an androgen receptor pathway inhibitor after these agents showed survival improvement in their landmark clinical trials. However, data are limited regarding the uptake of PARP inhibitors in these patients.ObjectiveTo investigate the use of PARP inhibitors in patients with mCRPC harboring BRCA1/2 alterations.Design, Setting, and ParticipantsThis retrospective cohort study used the deidentified Flatiron-Health electronic health record–derived database of US community and academic practices to extract patient-level data. The data cutoff date was May 31, 2024. Patients with mCRPC with evidence of harboring BRCA1/2 alterations and alive after August 15, 2020 (ie, 3 months after the approval of the first PARP inhibitor, rucaparib, in mCRPC) were included. Statistical analysis was performed from September 2024 to May 2025.ExposuresAge, race and ethnicity, insurance status, and practice type at the time of mCRPC diagnosis.Main Outcomes and MeasuresThe receipt of PARP inhibitors. Multivariable logistic regression was conducted to assess the association between the exposures and the main outcome.ResultsOf 24 105 patients with metastatic prostate cancer, 443 male patients (median [IQR] age, 72 [65-79] years) had mCRPC with BRCA1/2 alterations and were eligible and included in our analysis. Of these patients, 227 (51.2%) received a PARP inhibitor, whereas 216 (48.8%) did not. Compared with patients covered by a commercial health plan, those covered by Medicare were significantly more likely to receive a PARP inhibitor (odds ratio, 1.91; 95% CI, 1.02-3.66; P = .047). The odds of receiving a PARP inhibitor were not significantly higher in patients treated in community practice compared with those treated in academic centers (odds ratio, 1.64; 95% CI, 1.00-2.70; P = .05).Conclusions and RelevanceThis retrospective cohort study of patients with mCRPC and evidence of BRCA1/2 alterations found that approximately half of patients did not receive PARP inhibitors despite evidence of survival improvement in this population. These findings highlight the need to increase awareness of the survival data and access to life-prolonging therapies in patients with mCRPC.
The Definition of Cure in Colon Cancer
Pastorino, Alessandro , Liu, Heshan , Pederson, Levi , Martelli, Valentino , Gramont, Aimery de , Harkin, Andrea , Twelves, Chris , Souglakos, Ioannis , Goldberg, Richard M. , Puccini, Alberto , Sobrero, Alberto , Group, ACCENT/IDEA, Iveson, Timothy , Alberts, Steven R. , George, Thomas J. , Yothers, Greg , Labianca, Roberto , Taı̈eb, Julien , Schmoll, Hans‐Joachim , Wolmark, Norman , Saltz, Leonard B. , Goldberg, Richard M. , Kerr, Rachel , Lonardi, Sara , Yoshino, Takayuki , André, Thierry , Shi, Qian , Group, ACCENT/IDEA

Mayo Clinic

JAMA Oncology | October 2, 2025 | Volume: 11 | Issue: 12 | Pages: 1440

10.1001/jamaoncol.2025.3760 | PMID 41037274 Get It

Importance The definition of cure in stage II to III colon cancer (CC) remains unclear due to limitations in conventional end points, which include deaths and second primary tumors as events. These can complicate communication with patients regarding long-term outcomes. Objective To distinguish relapses from competing health-related events to classify long-term outcomes years after surgery and explore when the incidence of true relapses of the initial CC approaches 0% to define cure in this disease. Design, Setting, and Participants This pooled analysis of individual patient–level data from 15 phase 3 randomized clinical trials assessed time to CC-related relapse using Kaplan-Meier and Aalen-Johansen methods, with death and second primary tumors treated as competing risks. Cox regression models evaluated prognostic associations, stratified by sex, stage, and tumor. Patients with stage II to III CC who underwent adjuvant chemotherapy were included. All patients had undergone radical surgery for CC and received adjuvant chemotherapy with a median follow-up of at least 6 years. The Adjuvant Colon Cancer Endpoints (ACCENT) and the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) databases included adjuvant studies conducted between 1996 and 2015. Data were analyzed from February 2022 to June 2025. Exposures Adjuvant chemotherapy regimens varied across trials, including fluoropyrimidines alone or in combination with oxaliplatin or biologic agents. Main Outcomes and Measures The primary outcome was time to CC-related recurrence. The predefined threshold for cure was a recurrence risk below 0.5%. Results Of 35 213 included patients, 19 346 (54.9%) were male, and the mean (SD) age was 60.2 (10.8) years. The incidence rate of recurrence peaked at 6.4% (1993 of 31 373) between month 6 and month 12 and decreased continuously until year 10 of follow-up never exceeding 0.5%. Recurrence rate appeared to increase again after year 10 and peaked at 2.0% during year 12.5 to year 13, a pattern observed exclusively in the MOSAIC trial. Competing-event analysis revealed that death and second primary tumors inflated the apparent recurrence rate, especially for older patients. The overall cumulative incidence of relapse with death as competing risk was lower among female patients (hazard ratio, 0.58; 95% CI, 0.45-0.76; P &amp;lt; .001). Conclusions and Relevance In this pooled analysis of phase 3 randomized clinical trials, a recurrence rate less than 0.5% occurred after 6 years from surgery, supporting a practical definition of cure. Recognizing this milestone may improve patient communication, guide follow-up duration, and reduce unnecessary long-term surveillance.